# A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

> **NCT03650608** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Subject

## Interventions

- **DRUG:** Cohort 1: HL217 Ophathalmic Solution QD
- **DRUG:** Cohort 2: HL217 Ophathalmic Solution BID
- **DRUG:** Cohort 3: HL217 Ophthalmic Solution QID
- **DRUG:** Placebo Ophthalmic solution

## Key facts

- **NCT ID:** NCT03650608
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03650608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03650608, "A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03650608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*